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Abstract
Central nervous system injury induces a regenerative response in ensheathing glial cells
comprising cell proliferation, spontaneous axonal remyelination, and limited functional recov-
ery, but the molecular mechanisms are not fully understood. InDrosophila, this involves the
genes prospero andNotch controlling the balance between glial proliferation and differentia-
tion, and manipulating their levels in glia can switch the response to injury from prevention to
promotion of repair. In the mouse, Notch1 maintains NG2 oligodendrocyte progenitor cells
(OPCs) in a progenitor state, but what factor may enable oligodendrocyte (OL) differentiation
and functional remyelination is not understood. Here, we asked whether the mammalian
homologue of prospero, Prox1, is involved. Our data show that Prox1 is distributed in NG2+
OPCs and in OLs in primary cultured cells, and in the mouse spinal cord in vivo. siRNA prox1
knockdown in primary OPCs increased cell proliferation, increased NG2+OPC cell number
and decreased CC1+OL number. Prox1 conditional knockout in the OL cell lineage in mice
increased NG2+OPC cell number, and decreased CC1+OL number. Lysolecithin-induced
demyelination injury caused a reduction in CC1+OLs in homozygous Prox1-/- conditional
knockout mice compared to controls. Remarkably, Prox1-/- conditional knockout mice had
smaller lesions than controls. Altogether, these data show that Prox1 is required to inhibit
OPC proliferation and for OL differentiation, and could be a relevant component of the regen-
erative glial response. Therapeutic uses of glia and stem cells to promote regeneration and
repair after central nervous system injury would benefit frommanipulating Prox1.
Introduction
Glial cells proliferate throughout life in response to neuronal activity, conveying homeostatic
regulation of structure and function. NG2+ Oligodendrocyte Progenitor Cells (OPCs) prolifer-
ate and differentiate to produce oligodendrocytes (OLs), which ensheath and myelinate axons,
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provide trophic factors that maintain neuronal survival, regulate ion homeostasis and enable
saltatory conduction in the central nervous system (CNS) [1–5]. Disregulation of OPC and OL
number leads to gliomas and demyelinating diseases, like Multiple Sclerosis. CNS damage and
acute OL loss induce a robust regenerative response that promotes OPC proliferation, OL dif-
ferentiation and spontaneous remyelination [2,6,7]. This, however, does not culminate in full
functional repair as the lesion is invaded by microglia, macrophages and astrocytes that form
the glial scar, inhibit axonal growth, cause myelin breakdown and cell death [8,9]. Transplanta-
tion of glial cells to spinal cord injury lesions results in limited yet remarkable recovery of loco-
motion in mammals, including humans [10]. Thus, uncovering the molecular mechanisms
that control NG2+ OPC proliferation and their differentiation into OLs is essential to under-
stand CNS structural plasticity, the endogenous glial regenerative response to injury, and how
to enhance repair [2].
Notch1 is expressed in OPCs during development and in the adult, and it inhibits OL differ-
entiation maintaining OPCs in a progenitor state in culture and in vivo [11,12]. Notch1 condi-
tional-knock-out (CKO) in OPCs in mice induces OL differentiation [12], indicating that
Notch1 antagonises a factor that promotes OL differentiation. Yet, the involvement of Notch1
in the glial response to injury in the mouse is unresolved. Upon injury, Notch1 expression
increases in OPCs, correlating with OPC proliferation at the lesion boundaries, and with
remyelination in mice [13,14]. However, Notch1-CKO targeted to OPCs and OLs did not affect
the regenerative response to Cuprizone-induced or experimental autoimmune encephalomy-
elitis (EAE) demyelination in mice [13,15]. Nevertheless, the consensus is that injury induces
the proliferation of Notch1+ NG2+ OPCs in mammals, but it is unknown what factor may
antagonise Notch1 to drive OL differentiation conducive to re-myelination.
Drosophila is a powerful model organism to identify gene networks and function. The glial
regenerative response of neuropile-associated glia to CNS injury in fruit-flies requires the
antagonistic functions of the Notch1 homologue, Notch, and prospero (pros) [16,17]. Pros
inhibits glial proliferation and promotes differentiation, including morphology, axonal
enwrapment, and expression of glial differentiation markers such as Ebony and Glutamine
Synthetase 2 involved in neurotransmitter recycling. Notch inhibits glial differentiation and
promotes proliferation in flies. Nevertheless, glial proliferation in development and upon
injury requires both Pros and Notch, as although they have opposite effects on glia, they main-
tain each other’s expression, enabling differentiated glia to retain mitotic potential. This feed-
back loop between Notch and Pros provides a homeostatic mechanism to regulate glial
number in development and upon injury [17].
Whether mammalian OL lineage cells express the pros homologue, Prox1, and might influ-
ence the glial regenerative response to spinal cord injury, is unknown. Tentative evidence sug-
gests Prox1 could be involved. Prox1 promotes cell cycle exit and induces differentiation in many
contexts in mammals [18]. In the retina, Prox1 antagonises Notch1 function in the generation of
new neurons [19]. Prox1 was observed in OL lineage cells in the cortex of the mouse[20]. Clonal
analyses in mouse brains suggest that glioma originate from NG2+ OPCs, and glioma cells are
known to express Prox1 [21,22]. Thus, it was compelling to test the involvement of Prox1 in the
mammalian OL cell lineage. Here, we investigate the function of Prox1 in the OL cell lineage, and
in the glial regenerative response to demyelination in the adult mouse spinal cord.
Materials and Methods
Animals
Depending on the experiments, animal procedures were licensed by the UK Home Office and
approved by the University of Birmingham's Biomedical Ethics Review Sub-Committee, or
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reviewed and approved by the RIKEN Center for Developmental Biology, Japan. C57/BL6 mouse
were used for section preparation of spinal cords, and for OPC primary culture. Prox1-CKO
experiments were carried out using theOlig2-CreERmouse line, whereby theOlig2 promoter
drives expression of CRE-recombinase only in the OL cell lineage [23,24].Olig2CreER KImice
[24] and Prox1 F/Fmice were used [23]. In progeny mice from the two lines above, Tamoxifen
application induces the nuclear localisation of CreER Recombinase, leading to the flip-out only
in OPCs and OLs of the Prox1 cDNA, which had been inserted downstream of the 5’UTR, in the
first exon of the Prox1 gene. This resulted in the knock-out of the Prox1 coding region and the
expression of GFP under the control of the Prox1 promoter in the OL cell lineage. Prox1 F/+;
Olig2-CreER KI/+ and Prox1 F/Fmice were crossed to obtain experimental Prox1 F/F;Olig2-C-
reER KI/+mice and control Prox1 F/+;Olig2-CreER KI/+mice. Tamoxifen was applied to induce
Prox1 flip-out at week 5 after birth, and the spinal cords were harvested 5 weeks later. Genotyp-
ing was performed by PCR analysis with specific primers for theOlig2CreER allele (5’-TCGAGA
GCTTAGATCATCC-3’, 5’-AGCATTGCTGTCACTTGT-3’, 5’-CACCGCCGCCCAGTTTGTC
C-3’) and Prox1-CKO allele (5’-CAGCCCTTTTGTTCTGTTGGCC-3’, 5’-CAGATGCTGTCCC
TACCGTCC-3’).
We quantified the GFP+ cells, and found that whereas in Prox1-CKO+/- heterozygotes vir-
tually all GFP+ cells were Prox1+ (average 97% n = 6 mice), there was only a 30% reduction in
the percentage of Prox1+ cells amongst the GFP+ cells in Prox1-CKO-/- homozygous mice
(average 68%, n = 7 mice). As GFP is only detectable in the OL cell lineage if a knockout event
takes place, this would imply that Prox1 protein persists presumably due to its slow turnover.
The frequency of knock-out events also appears to have been rather low: only 4% of OL cell
lineage cells in the ventral funiculus of Prox1-CKO+/- heterozygous mice were GFP+, and only
3% were GFP+ in homozygotes (n = 6 and 7 mice respectively). This might have been due to
low Tamoxifen application.
Tamoxifen administration
To generate Prox1-CKO heterozygous/homozygous cells, Tamoxifen (3mg/mouse, Sigma), dis-
solved in peanut oil (Sigma) at a final concentration of 10 mg/ml, was applied by gavage to
Prox1 F/F;Olig2-CreER Kl/+mice and control Prox1 F/+;Olig2-CreER Kl/+mice twice at week
4. The spinal cords as intact samples were harvested at week 11, which received intraperitoneal
injection of 5mg/ml BrdU PBS solution (50mg/kg), 3 times a day with 2 hours interval, for four
days at 3 weeks before fixation. 3 mice (2 female, 1 male) for heterozygotes and 4 mice (2
female, 2 male) for homozygotes were sacrificed.
LPC induced demyelination
It has been previously shown that DNA synthesis occurs in OPCs approximately 3 days after
injury, and OL differentiation and remyelination occur by day 14 after LPC injection [25,26].
Thus, we applied Tamoxifen at week 5 after birth to induce the Prox1-CKO event, we injected
LPC or PBS (as a control) into the ventral funiculus of the spinal cords at week 8, applied BrdU
3 days later, and harvested the spinal cords at day 14 post-LPC-injection (week 10).
PBS injections in heterozygous (5 mice: 2 males, 3 females) and in homozygous mice (5
mice: 2 males, 3 females), and LPC injections in heterozygous (5 mice: 3males, 2 females) and
in homozygous mice (6 mice: 3 males, 3 females) were carried out. The mice were anaesthetised
with inhaled isoflurane/oxygen, supplemented with buprenorphine. Dorsal laminectomies
were performed at the level of T8/T9 vertebra. After the dura mater was incised transversely,
2μl of PBS (as a control) or 1% L-a-lysolecithin (Lysophosphatidylcholine; Sigma) PBS solution
were slowly delivered into the ventral funiculus by a grass capillary attached to a syringe. After
Prox1function in the Oligodendrocyte Cell Lineage
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2 days of injection, mice received intraperitoneal injection of 5mg/ml BrdU PBS solution
(50mg/kg); 3 times a day with 2 hours interval for 2 days. The mice were killed 14 days after
the PBS or LPC injection, and the spinal cords were harvested.
Antibodies
Antibodies used in this study were: rabbit anti-NG2 (1:400, Millipore), mouse anti-CC1 (CC-1,
1:400, MERC), sheep anti-BrdU (1:400, Exalpha Biologicals), mouse anti-MBP (1:4000, Cov-
ance), goat anti-Notch1ICD (1:50, Santa Cruz), goat anti-Prox1 (1:50, R & D system), rat anti-
PDGFRα (1:100, eBioscience), rat F4/80 (1:1000, Serotec), chick anti-GFP (1:2000, Aves),
mouse anti-GFP (1:400, Life Technologies), rabbit anti-GFP (1:500, Life Technologies), Alexa
488, 594, 647 conjugated donkey secondary antibodies (1:400, Life Technologies), biotinylated
donkey anti-goat and biotinylated donkey anti-chicken (1:400, Life Technologies), and Strepta-
vidin 488, 546 (1:400, Life Technologies).
Tissue preparation and immunostaining
Mice were killed by anaesthetic overdose, and perfusion fixed with 4% paraformaldehyde (TAAB
Laboratories). Subsequently, the spinal cords were dissected, fixed and cryoprotected with sucrose.
Then, they were embedded in OCT (Miles Inc.), and frozen with dry ice. Samples were sectioned
horizontally 15 μm thick at -20°C (Bright Instrument), collected on Vectabond coated slides (Vec-
tor laboratories), air dried, and maintained at -20°C. For immunostaining, the sections and cells
on coverslips from cell culture were washed with PBS, permeabilised with 0.3% Triton X-100
(Sigma), and blocked with 5% normal donkey serum (Sigma) or normal goat serum (Vector
laboratories). Sections were also blocked with donkey anti-mouse IgG Fc (1:100, Jackson Immu-
noresearch) when the mouse derived primary antibodies were used. Incubation with primary anti-
bodies was performed at 4°C overnight, and with fluorescent-conjugated secondary antibodies
was for 30 minutes at room temperature (RT). Nuclei were stained with DAPI (Sigma), and sam-
ples were mounted with 50% Glycerol. To detect BrdU, the sections/cells were treated with 2M
HCl for 20 minutes at RT after immunolabelling for other proteins and fixation. To detect MBP,
the sections were treated with 95% EtOH 5% Acetic Acid at RT for 15 min after immunolabelling
for other proteins and fixation. After washing and blocking, the sections were treated with anti-
MBP antibodies conjugated with Alexa fluor 546 (ZenonMouse IgG1 labelling kit, Life technolo-
gies), for 15 minutes at RT. Confocal microscopy was done with Leica SP2-AOBS confocal micro-
scope. Obtained images were analysed with ImageJ and processed with Photoshop (Adobe).
Cell culture
Mouse OPCs were purified from P0-P2 C57/BL6 mouse brains by the shaking method and we
achieved between 61 and 87% cell purity as in the original protocol [27,28]. OPCs were plated
at a density of 20,000 cells per 9 mm round Poly-ornithine coated coverslips (Sigma). They
were maintained in NBM OPC medium [28] with a slight modification; NBM (Life Technolo-
gies) supplemented with B27 (Life Technologies), 4mM L-Glutamine (Sigma), 1mM Sodium
Pyruvate (Sigma) and 10 ng/ml PDGF-AA (Peprotech). As a differentiation medium, NBM
supplemented with B27, 4mM L-Glutamine, Sodium Pyruvate, 10 ng/ml CNTF (Peprotech)
and 30 ng/ml T3 (Sigma) was used.
siRNA-mediated Gene silencing
Primary OPCs were transfected with Prox1-siRNA and Notch1-siRNA, and a day later were
shifted to a differentiation-inducing medium where they were maintained for 72 hours. On-
Prox1function in the Oligodendrocyte Cell Lineage
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TARGET plus siRNA SMARTpools (Thermo Fisher Scientific) against mouse Prox1 (L-
058437-01-0005, UGGAGAAGUAUGCGCGUCA, UAGCACAGGCUCCGAAGUA, AGUC
GAACGUACUCCGCAA, GAACAAGCCUAAGCGAGAA) and Notch1 (L-041110-00-0005,
GCCCGUGGAUUCAUCUGUA, AGACAGCUAUGCUACUUAU, GAGCGUAUGCACCA
CGAUA, CAAGAUUGAUGGCUACGAA) were transfected to OPCs using Ribocellin siRNA
Transfection Reagent (BiocellChallenge) at day-2 of primary culture. The medium containing
siRNA was replaced with differentiation medium at day-3. Subsequently, the medium was
replaced with differentiation medium containing 10μM BrdU (Sigma) at day-4, then the cells
were fixed at day-5. The efficiency of knockdown of Prox1 was determined in three indepen-
dent experiments by Immunostaining, followed by confocal microscopy with 40x lens and 4x
zoom on Leica SP6 confocal microscope.
Quantification and statistical analysis
Images stained by immunofluorescence were acquired using a Leica SP2-AOBS confocal
microscope. Image processing—thresholding, and measurement of area size and automatic
(ITCN plug-in)/manual counting of cells (cell counter plug-in)—were done using ImageJ.
For the cell count analysis on cell culture, 3 coverslips with primary OPCs were prepared
from each of three to four independent experiments. After immunostaining, more than
100 of cells per coverslip were scanned using a confocal microscope with a 40x lens. The
effects of gene knockdown in OPC primary culture were examined by counting the number
of NG2+, CC1+ and BrdU+. This was done manually using the cell counter plug-in and set-
ting the expression with threshold. For the analysis of spinal cords, we focused on the ventral
funiculus. Images were obtained with a 20x lens, and stitched using Fiji software to cover
the entire width and length of demyelinated area or equivalent area in intact spinal cords.
For cell number, the counts were made on two sections per animal when possible. The
numbers of Prox1 and DAPI were counted with the ITCN plug-in. The counts of CC1+,
GFP+, NG2+ and BrdU+ were done manually, and only when they colocallised with DAPI
(nuclear). For the count of cells in the demyelinated area, a region of interest (ROI) was set
to a 100μm wide band from the limits of nuclear-dense area (close approximate to the
demyelinated area). The NG2-positive pixels were measured within this ROI instead of cell
number because of difficulties of identifying cell bodies. For the LPC treatment experiments,
the MBP-negative area was measured from laser scanning confocal microscopy images
stained with anti-MBP, by drawing the outline of the lesion in ImageJ. Lesion volume was
estimated from bright field images of all the available spinal cord sections (i.e. using also sec-
tions that had not been stained with antibodies), taken using a Leica MZFLIII dissecting
microscope. The lesions were identified visually from the background white matter, and
they were comparable in shape and size to the MBP-negative areas in the stained sections of
each spinal cord. The lesion area was first measured by drawing the outline using ImageJ,
and the volume in each section was obtained by multiplying area by section thickness, 15μm.
The area in missing sections was extrapolated from adjacent sections. The total volume of
each lesion is the sum of the section lesion volumes in the series of sections, for each spinal
cord.
Statistical analyses were carried out using SPSS and GraphPad Prism software. When equal
variances could be assumed, the differences between groups were tested by unpaired, two-tailed
Student’s t-test (for two groups) or by One-Way ANOVA followed by multiple comparisons
Bonferroni post-hoc corrections (for more than two groups). Otherwise, unpaired, Mann-
Whitney U-tests were performed for two groups.
Prox1function in the Oligodendrocyte Cell Lineage
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Results
Prox1 is expressed in OPCs and OLs in primary cells and in vivo
To test whether in the mouse Prox1might be expressed in the OL cell lineage, we examined the
distribution of Prox1 protein in adult mouse spinal cords using anti-Prox1 antibodies and dou-
ble immunostaining with anti-NG2 to identify OPCs and anti-CC1 (CC1) for OLs. Whereas
most NG2-positive OPCs were Prox1-negative (Fig 1A and 1B), 31.9–48.6% of NG2+ OPCs
with dendritic processes also stained with anti-Prox1 (n = 105 scored NG2+ cells at 4 weeks of
age in one wild-type mouse; 48.6% is NG2+ Prox1+, and n = 150 NG2+ cells at 8 weeks in
Prox1-CKO+/- heterozygous intact 3 mice (see below); average: 31.9% NG2+ Prox1+/NG2)
(Fig1A and 1C). In contrast, virtually all CC1+ OLs in the white matter were also Prox1+ (Fig
1D and 1E) (n = 85 scored CC1+ cells; 94.1% CC1+ Prox1+/CC1+ in one wild-type mouse;
and n>500 CC1+Prox1+ cells in Prox1-CKO+/- heterozygous intact 3 mice (see below), aver-
age: 93.6% Prox1+CC1+/CC1+). The difference in Prox1+ expression in OPCs suggests either
that there are two types of OPCs (some NG2+ Prox1—and some NG2+ Prox1+) or that OPCs
gradually increase Prox1 protein levels over time to result in all OLs expressing Prox1 in vivo.
The invariable distribution in OLs suggests a prominent function for Prox1 in OLs.
Fig 1. Prox1 is distributed in the OL cell lineage in the mouse spinal cord. (A-C) Prox1 is distributed in
OL progenitor cells (OPC) as identified by colocalisation with NG2. (B,C) Higher magnification views showing
that some NG2+ cells have little or no Prox1 signal (B, arrows), whereas others have high Prox1 signal (C,
arrows). (D,E) Prox1 is distributed in OLs (OL) as identified by colocalisation with CC1. (E) Higher
magnification views, showing CC1+ Prox1+ cells (arrowheads). Scale bars: (A,D) 50μm; (B,C,E) 10μm.
doi:10.1371/journal.pone.0145334.g001
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Primary OPCs in culture were NG2+, Notch1+ (Fig 2A), and remarkably, also Prox1+ (Fig
2B). Consistent with the in vivo results, virtually all CC1+ OLs differentiated from purified pri-
mary OPCs, were also Prox1+ (Fig 2C).
Altogether, these data indicate that Prox1 expression in OPCs varies and Prox1 is promi-
nent and invariably distributed in differentiated OLs.
Prox1 inhibits OPC proliferation and is required for OL differentiation in
cell culture
To test what function might Prox1 have in the OL cell lineage, we asked whether Prox1 siRNA
knock-down might affect proliferation or differentiation of mouse primary OPCs in culture.
We transfected OPCs with Prox1-siRNA and Notch1-siRNA. In Prox1-siRNA transfected
OPCs, Prox1 signal was either weakened or undetectable compared to mock transfection con-
trols (Fig 2D, 71% Mock transfected OPCs are Prox1+ n = 31 scored cells vs. 16% of Prox1--
siRNA transfected OPCs n = 43 scored cells). To test whether Notch1-siRNA or Prox1-siRNA
affected OPC proliferation, the cell proliferation marker BrdU was applied. Whereas Notch1--
siRNA had no effect, transfection of primary OPCs with Prox1-siRNA resulted in a significant
increase in BrdU incorporation by NG2+ cells, compared to control (p<0.05) and to Notch1
knockdown (p<0.01), indicating that Prox1 inhibits OPC proliferation (Fig 2E and 2F)
(n = 100–200 cells scored for BrdU+, NG2+ and CC1+ per well, x 9–10 repeats). To test
whether Notch1 or Prox1 knockdown affected OPC differentiation into OLs, we quantified the
number of CC1+ OLs relative to total cell number [CC1+/(NG2+ and CC1+)] upon siRNA
transfection. Notch1-siRNA had no effect, but transfection of primary OPCs with Prox1-siRNA
resulted in a significant decrease in relative CC1+ OL cell number, compared to mock
(p<0.05) and Notch1 (p<0.01) transfections (Fig 2E and 2G), meaning that Prox1 is required
for OL differentiation. Consistently with the role of Notch1 in inhibiting OL differentiation
[14,29], our knockdown results suggested opposite functions for Prox1 and Notch 1 in the OL
lineage. In fact, BrdU+ and CC1+ cell counts differed significantly between Prox1-knockdown
and Notch1-knockdown, and to a greater extent than between Prox1-knockdown and mock
transfection controls (Fig 2F and 2G).
Altogether these data from primary cells in culture show that Prox1 inhibits NG2+ OPC
proliferation and is required for CC1+ OL differentiation.
Conditional knockout reveals that Prox1 is required for OL differentiation
in vivo
To ask whether Prox1 might also regulate OPC proliferation and differentiation in vivo, we used
Prox1 conditional knockout (Prox1-CKO) mice to delete the Prox1 gene only in the OL lineage
using theOlig2-CreERmouse line [23,24]. Upon Tamoxifen treatment, GFP is expressed under
the control of the endogenous Prox1 promoter. The mice of genotype Prox1Flox/+;; Olig2-CreER
can generate GFP+ Prox1-CKO+/- heterozygous cells, and Prox1Flox/Flox;Olig2-CreERmice can
generate GFP+ Prox1-CKO-/- homozygous mutant cells, within the OL lineage (Fig 3A). Consis-
tently with the above data from in vivo and primary OPCs, in heterozygous Prox1Flox/+;; Olig2-C-
reERmice, few GFP+ cells were NG2+ or PDGFRα+ OPCs with dendritic morphology (Fig 3B
and 3C), whilst most GFP+ cells were CC1+ OLs (Fig 3D). This confirms that Prox1 is expressed
in OPCs but most prominently in differentiated OLs.
In Prox1Flox/Flox;; Olig2-CreER homozygous mice (i.e. Prox1-CKO-/-), GFP+NG2+ OPCs
with dendritic morphology had weak or no Prox1 signal (Fig 3E and 3F), and CC1+ GFP+ OLs
could be either Prox1+ (Fig 3G) or Prox1− (Fig 3H), suggesting that the penetrance of knock-
out events was incomplete. Furthermore, not all Prox1-CKO-/- null mutant OPCs may be
Prox1function in the Oligodendrocyte Cell Lineage
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detectable with GFP. This is because Prox1 can regulate its own expression, thus Prox1-CKO
can lead to loss of Prox1-promoter activity and result in GFP-negative cells [23]. Thus, to
investigate the effects of Prox1-CKO we analysed the effects in total cell populations. Using
anti-Prox1 antibodies, we found a significant 5% reduction of Prox1+ cells in the ventral funic-
ulus of Prox1-CKO-/- homozygous mice compared to heterozygotes (Fig 3I, p<0.05).
We then asked how might Prox1-CKO affect NG2+ OPC and CC1+ OL cell number in vivo.
Conditional knockout in Prox1Flox/Flox;; Olig2-CreER homozygous mice resulted in an increase
in the relative number of NG2+ cells compared to heterozygous mice (Fig 3J, p<0.05). As we
had shown above that primary OPCs proliferate more upon Prox1 knock-down, this suggests
that Prox1-CKO-/- null OPCs proliferate more. In contrast, in Prox1-CKO-/- homozygous
mice there was no significant difference in the number of CC1+ OLs over the total cell popula-
tion (Fig 3K), but there was a significant reduction in the relative number of GFP+ CC1+ OLs
(Fig 3L, p<0.05), suggesting that Prox1 is required for normal CC1 expression and OL differ-
entiation. Altogether, Prox1-CKO in the OL cell lineage showed that Prox1 inhibits OPC pro-
liferation and/or NG2 expression and it is required for OL differentiation and/or CC1
expression.
Prox1 is required for OL differentiation upon LPC demyelination lesions
in adult spinal cords
Demyelinating lesions induce a glial regenerative response, that is, an increase in OPC prolifer-
ation, spontaneous OL differentiation and remyelination [30–33]. Thus, we wondered whether
Prox1-CKO would affect this response. Lysolecithin (LPC) is frequently used to induce demye-
lination in rodents, and demyelination is assessed by loss anti-Myelin Basic Protein (MBP) in
white matter [30,31,33]. To investigate the effect of Prox1-CKO in the glial regenerative
response to LPC lesions, we first tested whether tamoxifen application to induce Prox1-CKO
would in itself affect overall myelination and the MBP pattern in the spinal cord. Following
tamoxifen application at 4–5 weeks, the overall MBP pattern in the spinal cord of treated mice
did not change in Prox-CKO -/-mice compared to the heterozygous controls (Fig 4A and 4C).
Furthermore, Prox-CKO -/- cells were identified as GFP+ and they had MBP protein in their
projections (Fig 4B and 4D). Thus, tamoxifen treatment and Prox1-CKO did not in themselves
affect the overall MBP pattern.
LPC induced demyelination [32] was applied by injections into the spinal cord, in combina-
tion with BrdU incorporation (2 days post-LPC injection), in Prox1-CKOmice (Tamoxifen at
4–5 weeks, LPC injection at 8–9 weeks, perfusion at 14 days post-LPC injection). The largest
MBP negative lesions had epicenters that were sparsely populated with NG2+ and CC1+ cells,
consistently with reports that oligodendrogenesis progresses from the border of the lesions
Fig 2. Prox1 inhibits proliferation and is required for differentiation of primary OPCs. Immunostaining
of primary OPCs showing that NG2+ OPCs are (A) Notch1+, note that this anti-Notch1 antibody also detects
nuclear NotchICD and (B) Prox1+. (C) Prox1 is present in CC1+ OLs. (D, E) Prox1 knockdown by siRNA
reduces OL differentiation. (D) Control mock-transfected cells have Prox1, whereas in prox1-siRNA transfected
cells someOPCs retain Prox1 (arrowheads), other cells have dramatically reduced Prox1 (arrows). (E-G) In
differentiationmedium, control mock-transfected primary OPCs becamemostly CC1+ differentiated OLs,
whereas transfection with prox1-siRNA (Prox1KD) increased the proportion of NG2+BrdU+ cells, and
transfection withNotch1-siRNA (Notch1KD) increased the proportion of CC1+ cells (E). (F,G) Quantifications:
(F) mean number of BrdU+ amongst NG2+ cells, in control cells (mock) and upon transfection of Prox1-siRNA
(KD: knockdown) orNotch1-siRNA (N1 KD). (G) Mean ratio of CC1+ cells over the total cells (NG2+ CC1+) in
control cells (mock) and cells transfected with Prox1-siRNA (KD: knockdown) orNotch1-siRNA (KD). Error bars
represent standard error of the mean; asterisks: *p<0.05, **p<0.01. OneWay ANOVA p<0.05, followed by
Bonferroni post-hocmultiple comparison corrections. Sample sizes: mock: n = 9; Prox1-siRNA: n = 10;
Notch1-siRNA: n = 9. Scale bars: (A-D) 10mm, (E) 50mm.
doi:10.1371/journal.pone.0145334.g002
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[6,7,34]. Thus, we focused on a 100 μmwide band inward from the lesion border, which was
identified from the MBP-negative boundary and the boundary of high density DAPI+ nuclei
accumulation. There were fewer BrdU+ cells in Prox1-CKO-/- homozygotes than in heterozy-
gotes (Fig 5A and 5D, p<0.01)(see below). It was not possible to count the NG2+ cells, as the
NG2 immunoreactivity formed a continuous mesh over the entire lesion (Fig 5B), and individ-
ual cells could no longer be reliably distinguished, thus we measured the area covered by
Fig 3. Prox1-CKO in Olig2+ cells increased the number of OPCs and reduced OL number. (A) Diagram
illustrating that CKO in OL cell lineage results in the loss of Prox1 and the expression of GFP under the
endogenous Prox1 promoter. (B-D) Prox1CKO+/- knockout GFP+ heterozygous cells were generated in
Prox1F/+; Olig2-CreERmice within the OL cell lineage. (B,C) GFP was found in NG2+ Prox1+ (arrowheads; B)
and PDGFRα+ (arrowheads, C) OPCs. (D) GFP was found in CC1+ Prox1+ oligodencrocytes (arrowheads).
(E-H) After 7 weeks of tamoxifen application, weak anti-Prox1 signal was still detectable in some
GFP+NG2+OPCs (E, arrowheads), whilst others lacked any Prox1 signal (F, arrowheads). GFP+CC1+OLs
either had Prox1 (G, arrowheads), or very weak to no Prox1 signal (H, arrowheads). (I-K) Quantification of
Prox1+, NG2+ and CC1+ cells in the ventral funiculus of mouse spinal cords. (I) The number of Prox1+ cells
relative to the total, decreased in homozoygous Prox1-CKO-/-mice. (J) The number of NG2+OPCs relative to
total cell count increased in homozygous Prox1-CKO-/-mice. (K) The number of CC1+ cells relative to the total
does not change significantly in homozoygous Prox1-CKO-/-mice. (L) Box-plot showing that amongst the
Prox1-CKO-/- cells identified as GFP+ there was a reduction in CC1+ OLs. * p<0.05 (I,J) Student t-test; (L)
Mann-Whitney U-test; n = 6–7 mice. Error bar: standard error of the mean. (I-L) All areOlig2-CreER. (B-H)
Scale bar, 10 μm.
doi:10.1371/journal.pone.0145334.g003
Fig 4. The overall MBP pattern is not affected in tamoxifen treated intact Prox1 CKO spinal cords.
(A-D) Maximum projection of 2 confocal optical sections. Note that overlap of GFP+ processes and MBP
staning is observed in both Prox1-CKO+/- and Prox1 CKO-/- (arrowheads); MBP staining is less pronounced
in cell bodies, but its overall appearance is not distinguishable between the two genotypes. Scale bars: (A, C)
100 μm; (B, D) 10 μm.
doi:10.1371/journal.pone.0145334.g004
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NG2+ signal. The extent of NG2 distribution over the lesions was greater in Prox1-CKO-/-
homozygotes than in heterozygotes (Fig 5B and 5E p<0.05). Although net BrdU+ cell number
was reduced in Prox1-CKO-/- homozygotes, this suggests that in the absence of Prox1, LPC
lesions induced either increased OPC proliferation or NG2 expression by OLs. There were also
fewer CC1+ OLs in LPC-injected homozygous Prox1-CKO-/-mice than in the heterozygotes
(Fig 5C and 5F, p<0.001), showing that LPC treatment is a sensitized condition that enhances
the penetrance of the Prox1 loss of function phenotype. This further supports the notion that
Prox1 is required for OL differentiation.
Fig 5. LPC induced demyelination lesions in Prox-CKO-/- mutant mice had fewer OLs and greater
NG2+ area. (A-C) Immunostaining with (A) BrdU, (B) NG2 and (C) CC1, in LPC-induced lesions in the spinal
cords of Prox1-CKO+/- heterozygous (top) and Prox1-CKO-/- homozygous (bottom) mice, quantification in
(D-F). Note that lesions have a higher nuclear (DAPI) density than surrounding tissue. (A,D) Fewer
BrdU+ cells were observed within the lesions of Prox1-CKO-/-mutant mice. Prox1-CKO+/- n = 5 and
Prox1-CKO-/- n = 4. (B,E) Prox1-CKO-/- lesions had increased NG2+ signal area. Prox1-CKO+/- n = 9 and
Prox1-CKO-/- n = 8. (C,F) There were fewer CC1+ OLs within the lesions of Prox1-CKO-/-mice than in
controls. Prox1-CKO+/- n = 8 and Prox1-/- n = 6. *** p<0.001;** p<0.01; * p<0.05 Student t-test; error bar:
standard error of the mean. Dashed lines indicate the lesion boundary. Scale bar, 50 μm.
doi:10.1371/journal.pone.0145334.g005
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Interestingly, conditional Prox1-CKO altered demyelination lesion size. Mock PBS injection
did not induce demyelinated lesions in either Prox1-CKO heterozygous or homozygous mice
(Fig 6A and 6C), despite the injection sites being reliably identified by the small accumulation
of DAPI+ nuclei and F4/80+ activated macrophages or microglia (Fig 6A’ and 6C’). LPC
injection in Prox1-CKO+/- heterozygous mice caused large MBP-negative lesions (Fig 6B).
Consistently with previous studies, MBP− lesions were packed with DAPI+ nuclei and F4/80+
macrophages/microglia (Fig 6B and 6B’). In contrast, MBP− lesions were significantly smaller
in Prox1-CKO-/- homozygous mice (Fig 6D, 6E and 6G) so that in extreme cases, the MBP−
area was almost the same size as those in PBS-injection lesions, and with similar accumulations
of DAPI+ and F4/80+ cells (Fig 6E and 6E’). Consistently, the estimated total lesion volume
also significantly decreased in Prox1 CKO-/- homozygotes (Fig 6G, p<0.05; average estimated
lesion volume: Prox1-CKO+/- 0.45 mm3 vs. Prox1CKO-/- 0.11mm3). These data suggested that
Prox1-CKO-/- had a protective effect against LPC-induced injury.
The smaller lesions size and reduced accumulation of F4/80+ cells in Prox1-CKO-/- homo-
zygous mutants might suggest that the net observed reduction in BrdU+ cells could have been
due to a requirement for Prox1 in the proliferation of macrophages/microglia upon LPC
induced lesions, resembling its function in OPCs. In fact, LPC treatment activates microglia
that attack the myelin sheath, increasing lesion size [9,32,33,35]. However, Olig2Cre does not
drive expression in microglia [36]. Furthermore, although there was a dramatic accumulation
of F4/80+ active microglia/macrophages in LPC induced lesions in Prox1-CKO+/- heterozy-
gotes, none of these cells co-distributed GFP with F4/80 (Fig 6F Prox1-GFP, n = 5), confirming
that the Olig2 promoter does not drive expression in microglia/macrophages, and revealing
that Prox1 is not localised in these cell types under these experimental conditions. This means
that Olig2-driven Prox1-CKO could not directly affect microglial/macrophage number, fate or
migration. Alternatively, the reduction in microglia/macrophages could be an indirect effect of
Prox1mutant OLs or OPCs (see discussion). Together, our data showed that upon LPC-
induced demyelination, Prox1-CKO-/- in OL lineage cells led to the downregulation of CC1,
upregulation of NG2, and prevented the formation of large demyelinated lesions.
Discussion
Our data show that in the mammalian spinal cord, Prox1 inhibits OPC proliferation, is
required for OL differentiation, and is involved in the glial regenerative response to demyelin-
ation injury (Fig 7).
We have shown that Prox1 is distributed in NG2+ and PDGFRα+ OPCs, and in CC1+
OLs in wild-type mouse spinal cords, in mouse primary cultured OPCs and in heterozygous
Prox1Flox/+;; Olig2-CreER control mice in vivo. Whereas the distribution of Prox1 in NG2
+ PDGFRα+ OPCs varied, virtually all CC1+ OLs had Prox1. Most likely, Prox1 is first
expressed in OPCs, and protein levels increase over time, leading to OL differentiation. How-
ever, there is also cell type heterogeneity within the NG2+ cells, as not all of them in the white
matter of the adult brain have mitotic potential, some behave as neural stem cells, and they can
also differ in physiology [37]. Thus, perhaps Prox1 may be another indicator for two types of
OPC populations. Prox1 expression has also been reported in oligodendrocyte lineage cells of
the brain cortex [20]. Thus, together with our data, this indicates that Prox1 is present in the
oligodendrocyte cell lineage throughout the mammalian CNS. Importantly, our data show that
Prox1 is characteristic of differentiated OLs.
Our data showed that Prox1 inhibits OPC proliferation and is required for OL differentia-
tion. Loss of Prox1 function increased OPC proliferation in primary OPCs, as the number of
NG2+ OPCs with incorporated BrdU increased upon Prox1 siRNA knock-down compared to
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controls. NG2+ OPC cell number also increased in Prox1-CKO-/- in mice in vivo. The increase
in OPC number upon loss of Prox1 in vivo is most likely due to induced OPC over-prolifera-
tion and failed OL differentiation. In fact, we have shown that Prox1 is required for OL differ-
entiation. Loss of Prox1 function led to fewer OLs both upon siRNA Prox1 knockdown in
primary OPCs, and in Prox1-CKO in the OL cell lineage in mice in vivo. The expression and
loss of function analyses showed that Prox1 is present in all OLs and is required for their main-
tenance and differentiation.
Conceivably, Prox1 could regulate the above events by antagonizing Notch1 function in the
OL cell lineage (Fig 6A and 6B). Like others [13,14], we also found Notch1 in mammalian pri-
mary OPCs in cell culture and in vivo, and that over-expression or knockdown of Notch1 in
primary OPC cell culture had no effect. Remarkably, however, knockdown of Prox1 and
Notch1 had opposite effects on proliferating OPCs versus OLs, and the difference between
their effects was greater than the difference between Prox1-knockdown and the control. In
Drosophila Interface glia, Pros and Notch antagonize each other’s function in cell proliferation
and differentiation, whilst also maintaining each other’s expression [16,17]. In this way, as
their expression is maintained through positive feedback, their antagonistic functions provide
negative feedback, creating a homeostatic control of glial cell number. Functional relationships
between Prox1 and Notch1 might take place in the mouse OL lineage, but they are unlikely to
be identically conserved (Fig 7A and 7B). InDrosophila there is no difference between glial pro-
genitors and differentiated glia. Instead, differentiated interface glia enwrap the neuropile and
Fig 6. LPC induced demyelination in the spinal cord of Prox1-CKOmice resulted in smaller lesions. (A-E) LPC injection in the spinal cord induced
demyelination lesions in the white matter visualised as anti-MBP-negative areas (arrowheads), which were smaller in Prox1-CKO-/-mice compared to
heterozygous controls (compare B with D and E). In 2 out of 6 Prox1-CKO-/-mice, the MBP-negative lesions were extremely small (E). Nuclear staining with
DAPI revealed high cell density within the MBP-negative areas. (A’-E’) High magnification details of the MBP-negative lesions indicated by arrowheads in
(A-E), which accumulated F4/80+ macrophages. (F) GFP+ F4/80+ cells are not found in Prox1-CKO+/-, suggesting Prox1 does not directly influence
macrophages in this context. (G) Bar graphs showing that upon PBSmock injection (left) MBP-negative lesions are comparable in size in control and
Prox1-CKO-/-mice, but upon LPC injection (right) demyelinated MBP–areas are smaller in Prox1-CKO-/-mice. Total lesion volume (far right) was also
reduced in Prox1-CKO-/- homozygotes compared to the heterozygous animals. Genotypes: Control: Prox1F/+, Olig2-CreER and Prox1-CKO-/-: Prox1F/F,
Olig2-CreER. GM: gray matter; LPC: lysolecithin. * p<0.05, Student t-test. Sample sizes: control, n = 5; Prox1-CKO-/-, n = 6; Horizontal sections, rostral is up,
scale bar: 500 μm.
doi:10.1371/journal.pone.0145334.g006
Fig 7. Prox1 function in the OL cell lineage. (A) Comparison of Drosophila enwrapping interface glia (IG) and mammalian OPCs and OLs. Drosophila glia
are differentiated cells that enwrap axons, recycle neurotransmitters, proliferate upon injury and express bothNotch and pros. OPCs are proliferative
progenitors and have both Notch1 and Prox1. OLs are differentiated cells that myelinate axons, and have Prox1. (B) In Drosophila IG, Pros and Notch
maintain each other’s expression but have opposite functions in cell proliferation and differentiation. This maintains these cells quiescent but ready to divide
upon injury. In the mouse, hypothetical interactions between Prox1 and Notch1 are given: arrows in black indicate evidence presented here as data or based
on OL cell lineage literature, and dotted in grey indicate hypothetical genetic interactions. Accumulation of Prox1 protein in OPCs could drive cell cycle exit,
repress NG2 expression, and drive OL differentiation. Prox1 may be required in OLs to maintain differentiation and function.
doi:10.1371/journal.pone.0145334.g007
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axons, proliferate upon injury, and have both Notch and Pros. In mammals, OPCs and OLs are
distinct cell states, and whereas OPCs can have both Notch1 and Prox1, OLs have only Prox1.
The functional relationship between Notch1 and Prox1 in the mammalian OL lineage could
regulate the transition from dividing OPCs to differentiating OLs, as Prox1 levels rise to drive
cell cycle exit and differentiation.
Although we observed increased proliferation when Prox1 was knocked-down in cultured
OPCs, fewer BrdU+ cells were detected within the lesions of Prox1-CKOmice, than in controls.
The overall reduction in BrdU+ cells could correspond to decreased proliferation of macro-
phages/microglia in Prox1-CKOmice, consistently with the smaller nuclei-dense areas upon
LPC injection in the homozygous mutants. Nevertheless, OPCs may have proliferated less in
Prox1-CKO -/- at a time of BrdU treatments, which can be explained in two ways. First, in Dro-
sophila, prosmutant glia do not divide more times, but divide faster skipping the G1 phase
[16,17]. Similarly, when we applied BrdU, OPCs may have already gone through S-phase, lead-
ing to an under-representation of the extent of cell division. Alternatively, genetic interactions
involving a proliferation activator and Prox1 may be involved. In Drosophila, although Pros
inhibits glial proliferation, Pros is required for glial proliferation to take place [16,17]. Whilst
injury in the Drosophila CNS normally provokes glial proliferation, in prosmutants there is a
relative reduction in the number of glial cells after injury instead [16,17]. This is because in the
absence of Pros, Notch signaling also decreases. Furthermore, whilst NFκB triggers cell prolif-
eration upon injury, its expression also depends on Pros [17]. Thus, in prosmutants, there is a
reduction in both NFκB and Notch levels, and consequently glial cells cannot proliferate in
response to injury [17]. In mouse brains, only half of OPCs are proliferative [38,39] and coinci-
dently only half of OPCs expressed Prox1 in spinal cords, whilst in primary cultures all OPCs
were potentially proliferative and expressed Prox1. Hence, like in fruit-flies and possibly in
human brain tumours [21,22], Prox1 might confer mammalian glia with proliferative potential.
If Prox1 –most likely indirectly—were to activate the expression of proliferation activators,
then loss of Prox1 could lead to an initial increase in proliferation followed by a loss of mitotic
potential, preventing injury-induced regenerative proliferation (Fig 7B).
Our data also revealed statistically significant differences in LPC lesion size between
Prox1-CKO-/- homozygous and heterozygous mice. NG2 protein levels increased and spread
over a larger area in demyelinated Prox1-CKO-/-mice than in controls. It is known that
increased NG2 leads to increased OPC proliferation [40,41]. Thus, conceivably, in Prox1-CKO
undetected increased OPC proliferation may correlate with smaller lesion size. Alternatively,
the smaller lesion size in Prox1-CKO-/-mice could also be due to decreased lesion expansion.
LPC lesions are caused by dissolution of membrane lipids, and myelin breakdown by activated
T-cells, microglia and macrophages, which invade the lesions, attack myelin, inhibit OPC pro-
liferation, NG2 function and axonal growth, causing lesion expansion and preventing regener-
ation and repair [9,30,32,33,35,42–49]. Similarly to our findings, NG2 knockout mice also have
smaller lesions compared to controls, and this was caused by reduced infiltration of microglia
[41]. NG2 is expressed in microglia and is required for their migration, hence resulting in
reduced microglia invasion in the mutant [41]. In Prox1-CKO-/-mice the lesions also had
fewer F4/80 cells, thus perhaps secondary damage and lesion expansion did not take place
either. In lesioned Prox1-CKO-/-mice, invasion by microglia and macrophages might have
been mitigated by their reduced proliferation, or reduced T-cell activation. These would require
both Olig2 and Prox1 to be normally expressed in microglia/macrophages–which we found not
to be the case–and in T-cells, which is unknown. Whilst this indicates that Prox1 may not
directly affect microglia/macrophages, it could still affect them indirectly. In a similar scenario,
loss of Cgt—which is highly expressed in OLs, and is required for the major component of
myelin sheath galactocerebrosides—in knock-out mutant mice, causes a defect in nerve
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conduction as well as defective postnatal lymphopoiesis [50]. It has been shown that the ner-
vous system, most particularly glial cells, controls hematopoietic stem and progenitor cells exit
from bone marrow niches [50,51]. Therefore, conceivably Prox1-CKO in the OL lineage may
indirectly influence immune cells. In any case, the most remarkable finding was that in
Prox1-CKO-/-mice the smaller lesions had higher and broader NG2+ coverage. NG2 can pro-
tect against the destructive effects of macrophages [52]. Thus, our data suggest that in spinal
cord demyelination, the down-regulation of Prox1 in the OL lineage causes the up-regulation
of NG2, which is protective.
To conclude, the data show that Prox1 regulates proliferation and differentiation of the OL
cell lineage, and is a relevant component of the endogenous regenerative response to CNS
injury. The relationship between Prox1 and NG2 in CNS repair warrants further attention.
Acknowledgments
We are grateful to Zubair Ahmed, Arthur Butt, Alessandro Di Maio, Daniel Fulton, Ana Maria
Gonzalez, Daljeet Mahay, Akiko Nishiyama, Andy Thewles, for technical help and advice;
Michael Douglas for reagents.
Author Contributions
Conceived and designed the experiments: KK AH AL FM. Performed the experiments: KK DK
MB. Analyzed the data: KK. Contributed reagents/materials/analysis tools: AL MB DK FM.
Wrote the paper: AH KK AL FM DKMB. Conceived and directed the project: AH AL.
References
1. Ffrench-Constant C, Raff MC (1986) The oligodendrocyte-type-2 astrocyte cell lineage is specialized
for myelination. Nature 323: 335–338. PMID: 3531873
2. Franklin RJ, Ffrench-Constant C (2008) Remyelination in the CNS: from biology to therapy. Nat Rev
Neurosci 9: 839–855. doi: 10.1038/nrn2480 PMID: 18931697
3. Trotter J, Karram K, Nishiyama A (2010) NG2 cells: properties, progeny and origin. Brain Res Rev 63:
72–82. doi: 10.1016/j.brainresrev.2009.12.006 PMID: 20043946
4. Nishiyama A, Komitova M, Suzuki R, Zhu X (2009) Polydendrocytes (NG2 cells): multifunctional cells
with lineage plasticity. Nature Reviews Neuroscience 10: 9–22. doi: 10.1038/nrn2495 PMID:
19096367
5. Nave KA (2010) Myelination and the trophic support of long axons. Nat Rev Neurosci 11: 275–283.
doi: 10.1038/nrn2797 PMID: 20216548
6. Tripathi R, McTigue DM (2007) Prominent oligodendrocyte genesis along the border of spinal contusion
lesions. Glia 55: 698–711. PMID: 17330874
7. Chari DM, Blakemore WF (2002) Efficient recolonisation of progenitor-depleted areas of the CNS by
adult oligodendrocyte progenitor cells. Glia 37: 307–313. PMID: 11870870
8. Sharma K, Selzer ME, Li S (2012) Scar-mediated inhibition and CSPG receptors in the CNS. Exp Neu-
rol 237: 370–378. doi: 10.1016/j.expneurol.2012.07.009 PMID: 22836147
9. Fitch MT, Doller C, Combs CK, Landreth GE, Silver J (1999) Cellular and molecular mechanisms of
glial scarring and progressive cavitation: in vivo and in vitro analysis of inflammation-induced secondary
injury after CNS trauma. J Neurosci 19: 8182–8198. PMID: 10493720
10. Granger N, Franklin RJ, Jeffery ND (2014) Cell therapy for spinal cord injuries: what is really going on?
The Neuroscientist 20: 623–638. doi: 10.1177/1073858413514635 PMID: 24415275
11. Wang S, Sdrulla AD, diSibio G, Bush G, Nofziger D, Hicks C, et al. (1998) Notch receptor activation
inhibits oligodendrocyte differentiation. Neuron 21: 63–75. PMID: 9697852
12. Genoud S, Lappe-Siefke C, Goebbels S, Radtke F, Aguet M, Scherer SS, et al. (2002) Notch1 control
of oligodendrocyte differentiation in the spinal cord. J Cell Biol 158: 709–718. PMID: 12186854
13. Stidworthy M, Genoud S, Li W-W, Leone D, Mantei N, Suter U, et al. (2004) Notch1 and Jagged1 are
expressed after CNS demyelination, but are not a major rate-determining factor during remyelination.
Brain 127: 1928–1941. PMID: 15289265
Prox1function in the Oligodendrocyte Cell Lineage
PLOS ONE | DOI:10.1371/journal.pone.0145334 December 28, 2015 17 / 19
14. Genoud S, Lappe-Siefke C, Geobbels S, Radtke F, Aguet M, Scherer SS, et al. (2002) Notch1 control
of oligodendrocyte differentiation in the spinal cord. J Cell Biol 158: 709–718. PMID: 12186854
15. Seifert T, Bauer J, Weissert R, Fazekas F, Storch MK (2006) Notch1 and its ligand Jagged1 are present
in remyelination in a T-cell- and antibody-mediated model of inflammatory demyelination. Acta Neuro-
pathol 113: 195–203. PMID: 17136549
16. Griffiths RL, Hidalgo A (2004) Prospero maintains the mitotic potential of glial precursors enabling them
to respond to neurons. EMBO J 23: 2440–2450. PMID: 15167898
17. Kato K, Forero MG, Fenton JC, Hidalgo A (2011) The glial regenerative response to central nervous
system injury is enabled by pros-notch and pros-NFκB feedback. PLOS Biol 9: e1001133. doi: 10.
1371/journal.pbio.1001133 PMID: 21912512
18. Dyer MA, Livesey FJ, Cepko CL, Oliver G (2003) Prox1 function controls progenitor cell proliferation
and horizontal cell genesis in the mammalian retina. Nature Genetics 34: 53–58. PMID: 12692551
19. Kaltezioti V, Kouroupi G, Oikonomaki M, Mantouvalou E, Stergiopoulos A, Charonis A, et al. (2010)
Prox1 regulates the Notch-1 mediated inhibition of neurogenesis. PLOS Biol 8: e1000565. doi: 10.
1371/journal.pbio.1000565 PMID: 21203589
20. Rubin AN, Kessaris N (2013) PROX1: a lineage tracer for cortical interneurons originating in the lateral/
caudal ganglionic eminence and preoptic area. PLOSONE 8: e77339. doi: 10.1371/journal.pone.
0077339 PMID: 24155945
21. Elsir T, Smits A, LindstromMS, Nister M (2012) Transcription factor PROX1: its role in development
and cancer. Cancer Metastasis Rev 31: 793–805. doi: 10.1007/s10555-012-9390-8 PMID: 22733308
22. Persson AI, Petritsch C, Swartling FJ, Itsara M, Sim FJ, Auvergne R, et al. (2010) Non-stem cell origin
for oligodendroglioma. Cancer Cell 18: 669–682. doi: 10.1016/j.ccr.2010.10.033 PMID: 21156288
23. Iwano T, Masuda A, Kiyonari H, Enomoto H, Matsuzaki F (2012) Prox1 postmitotically defines dentate
gyrus cells by specifying granule cell identity over CA3 pyramidal cell fate in the hippocampus. Devel-
opment 139: 3051–3062. doi: 10.1242/dev.080002 PMID: 22791897
24. Takebayashi H, Nabeshima Y, Yoshida S, Chisaka O, Ikenaka K, Nabeshima Y (2002) The basic helix-
loop-helix factor Olig2 is essential for the development of motoneuron and oligodendrocyte lineages.
Current Biology 12: 1157–1163. PMID: 12121626
25. Fancy SP, Harrington EP, Yuen TJ, Silbereis JC, Zhao C, Baranzini SE, et al. (2011) Axin2 as regula-
tory and therapeutic target in newborn brain injury and remyelination. Nat Neurosci 14: 1009–1016.
doi: 10.1038/nn.2855 PMID: 21706018
26. Simon C, Gotz M, Dimou L (2011) Progenitors in the adult cerebral cortex: cell cycle properties and reg-
ulation by physiological stimuli and injury. Glia 59: 869–881. doi: 10.1002/glia.21156 PMID: 21446038
27. O'Meara RW, Ryan SD, Colognato H, Kothary R (2011) Derivation of enriched oligodendrocyte cultures
and oligodendrocyte/neuron myelination co-cultures from post-natal murine tissues. JoVE 54: e3324.
28. Yang Z, Watanabe M, Nishiyama A (2005) Optimization of oligodendrocyte progenitor cell culture
method for enhanced survival. J Neurosci Meth 149: 50–56.
29. Wang S, Sdrulla AD, diSibio G, Bush G, Nofziger D, Hicks C, et al. (1998) Notch receptor activation
inhibits oligodendrocyte differentiation. Neuron 21: 63–75. PMID: 9697852
30. Birgbauer E, Rao TS, Webb M (2004) Lysolecithin induces demyelination in vitro in a cerebellar slice
culture system. J Neurosci Res 78: 157–166. PMID: 15378614
31. BlakemoreWF, Eames RA, Smith KJ, McDonald WI (1977) Remyelination in the spinal cord of the cat
following intraspinal injections of lysolecithin. J Neurol Sci 33: 31–43. PMID: 903788
32. BlakemoreWF, Franklin RJ (2008) Remyelination in experimental models of toxin-induced demyelin-
ation. Curr Top Microbiol Immunol 318: 193–212. PMID: 18219819
33. Hall SM (1972) The effect of injections of lysophosphatidyl choline into white matter of the adult mouse
spinal cord. J Cell Sci 10: 535–546. PMID: 5018033
34. Hesp ZC, Goldstein EA, Miranda CJ, Kaspar BK, McTigue DM (2015) Chronic Oligodendrogenesis and
Remyelination after Spinal Cord Injury in Mice and Rats. J Neuroscience 21: 1274–1290.
35. Ghasemlou N, Jeong SY, Lacroix S, David S (2007) T cells contribute to lysophosphatidylcholine-
induced macrophage activation and demyelination in the CNS. Glia 55: 294–302. PMID: 17096403
36. IslamMS, Tatsumi K, Okuda H, Shiosaka S, Wanaka A (2009) Olig2-expressing progenitor cells prefer-
entially differentiate into oligodendrocytes in cuprizone-induced demyelinated lesions. Neurochem Int
54: 192–198. doi: 10.1016/j.neuint.2008.10.011 PMID: 19070638
37. Dimou L, Götz M (2014) Glial cells as progenitors and stem cells: new roles in the healthy and diseased
brain. Physiol Rev 94: 709–737. doi: 10.1152/physrev.00036.2013 PMID: 24987003
38. Kukley M, Kiladze M, Tognatta R, Hans M, Swandulla D, Schramm J, et al. (2008) Glial cells are born
with synapses. FASEB J 22: 2957–2969. doi: 10.1096/fj.07-090985 PMID: 18467596
Prox1function in the Oligodendrocyte Cell Lineage
PLOS ONE | DOI:10.1371/journal.pone.0145334 December 28, 2015 18 / 19
39. Rivers LE, Young KM, Rizzi M, Jamen F, Psachoulia K, Wade A, et al. (2008) PDGFRA/NG2 glia gen-
erate myelinating oligodendrocytes and piriform projection neurons in adult mice. Nat Neurosci 11:
1392–1401. doi: 10.1038/nn.2220 PMID: 18849983
40. Chekenya M, Pilkington GJ (2002) NG2 precursor cells in neoplasia: functional histogenesis and thera-
peutic implications for malignant brain tumours. Journal of Neurocytology 31: 507–521. PMID:
14501220
41. Kucharova K, Chang Y, Boor A, Yong VW, StallcupWB (2011) Reduced inflammation accompanies
diminished myelin damage and repair in the NG2 null mouse spinal cord. J Neuroinflammation 8: 158.
doi: 10.1186/1742-2094-8-158 PMID: 22078261
42. Akbik F, Cafferty WB, Strittmatter SM (2012) Myelin associated inhibitors: a link between injury-induced
and experience-dependent plasticity. Exp Neurol 235: 43–52. doi: 10.1016/j.expneurol.2011.06.006
PMID: 21699896
43. Horn KP, Busch SA, Hawthorne AL, van Rooijen N, Silver J (2008) Another barrier to regeneration in
the CNS: activated macrophages induce extensive retraction of dystrophic axons through direct physi-
cal interactions. J Neurosci 28: 9330–9341. doi: 10.1523/JNEUROSCI.2488-08.2008 PMID:
18799667
44. Keough MB, Jensen SK, Yong VW (2015) Experimental demyelination and remyelination of murine spi-
nal cord by focal injection of lysolecithin. J Vis Exp. doi: 10.3791/52679
45. Kotter MR, Setzu A, Sim FJ, Van Rooijen N, Franklin RJ (2001) Macrophage depletion impairs oligo-
dendrocyte remyelination following lysolecithin-induced demyelination. Glia 35: 204–212. PMID:
11494411
46. Miron VE, Boyd A, Zhao JW, Yuen TJ, Ruckh JM, Shadrach JL, et al. (2013) M2 microglia and macro-
phages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci 16: 1211–1218.
doi: 10.1038/nn.3469 PMID: 23872599
47. Ousman SS, David S (2000) Lysophosphatidylcholine induces rapid recruitment and activation of mac-
rophages in the adult mouse spinal cord. Glia 30: 92–104. PMID: 10696148
48. Trotter J, Smith ME (1986) The role of phospholipases from inflammatory macrophages in demyelin-
ation. Neurochem Res 11: 349–361. PMID: 3486373
49. Weltzien HU (1979) Cytolytic and membrane-perturbing properties of lysophosphatidylcholine. Biochim
Biophys Acta 559: 259–287. PMID: 476122
50. Katayama Y, Battista M, KaoWM, Hidalgo A, Peired AJ, Thomas SA, et al. (2006) Signals from the
sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell 124:
407–421. PMID: 16439213
51. Yamazaki S, Ema H, Karlsson G, Yamaguchi T, Miyoshi H, Shioda S, et al. (2011) Nonmyelinating
Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell 147:
1146–1158. doi: 10.1016/j.cell.2011.09.053 PMID: 22118468
52. Busch SA, Horn KP, Cuascut FX, Hawthorne AL, Bai L, Miller RH, et al. (2010) Adult NG2+ Cells Are
Permissive to Neurite Outgrowth and Stabilize Sensory Axons during Macrophage-Induced Axonal
Dieback after Spinal Cord Injury. J Neuroscience 30: 255–265. doi: 10.1523/JNEUROSCI.3705-09.
2010 PMID: 20053907
Prox1function in the Oligodendrocyte Cell Lineage
PLOS ONE | DOI:10.1371/journal.pone.0145334 December 28, 2015 19 / 19
